Last kr12.55 SEK
Change Today +0.15 / 1.21%
Volume 76.5K
KDEV On Other Exchanges
Symbol
Exchange
Stockholm
As of 11:30 AM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

karolinska development-b (KDEV) Snapshot

Open
kr12.70
Previous Close
kr12.40
Day High
kr13.00
Day Low
kr12.55
52 Week High
03/7/14 - kr28.00
52 Week Low
10/21/14 - kr10.20
Market Cap
670.0M
Average Volume 10 Days
41.4K
EPS TTM
kr-7.75
Shares Outstanding
51.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KAROLINSKA DEVELOPMENT-B (KDEV)

Related News

No related news articles were found.

karolinska development-b (KDEV) Related Businessweek News

No Related Businessweek News Found

karolinska development-b (KDEV) Details

Karolinska Development AB (publ) is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark. It prefers to be a lead investor in its portfolio companies however does consider co-investments also. It seeks to invest in up to five projects annually. Karolinska Development AB (publ) was founded in 2003 and is headquartered in Stockholm, Sweden.

karolinska development-b (KDEV) Top Compensated Officers

Acting Chief Executive Officer
Total Annual Compensation: kr2.2M
Compensation as of Fiscal Year 2013.

karolinska development-b (KDEV) Key Developments

Karolinska Development AB (publ), 2014 Earnings Call, Feb 18, 2015

Karolinska Development AB (publ), 2014 Earnings Call, Feb 18, 2015

Karolinska Development AB (publ) Announces Unaudited Consolidated and Parent Company Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Karolinska Development AB (publ) announced unaudited consolidated and parent company earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, on consolidated basis, the company reported revenue of SEK 1,580,000 compared to SEK 945,000 a year ago. Operating loss was SEK 40,315,000 compared to SEK 138,666,000 a year ago. Loss before tax was SEK 39,801,000 compared to SEK 99,190,000 a year ago. Net loss for the period was SEK 39,801,000 or SEK 0.80 per basic and diluted share compared to SEK 99,190,000 or SEK 2.05 per basic and diluted share a year ago. For the year, on consolidated basis, the company reported revenue of SEK 5,030,000 compared to SEK 4,948,000 a year ago. Operating loss was SEK 372,216,000 compared to SEK 198,744,000 a year ago. Loss before tax was SEK 375,815,000 compared to SEK 157,315,000 a year ago. Net loss for the period was SEK 375,815,000 or SEK 7.73 per basic and diluted share compared to SEK 157,315,000 or SEK 3.25 per basic and diluted share a year ago. Cash flow used in operating activities was SEK 108,387,000 compared to SEK 70,874,000 a year ago. For the quarter, the parent company reported revenue of SEK 1,580,000 compared to SEK 1,567,000 a year ago. Operating loss was SEK 21,403,000 compared to SEK 17,366,000 a year ago. Net loss for the period was SEK 20,575,000 compared to SEK 16,187,000 a year ago. For the year, the parent company reported revenue of SEK 5,030,000 compared to SEK 4,948,000 a year ago. Operating loss was SEK 76,780,000 compared to operating profit of SEK 7,459,000 a year ago. Net loss for the period was SEK 78,130,000 compared to net profit of SEK 47,314,000 a year ago.

Karolinska Development AB, KDev Oncology AB, Aprea AB and Akinion Pharmaceuticals AB Announce Executive Changes

Karolinska Development AB announced that the company's CEO Bruno Lucidi leaves the company. He is replaced by Deputy CEO Terje Kalland until a new, permanent CEO is appointed. The recruitment process for a permanent CEO has been initiated. At the same time, Bruno Lucidi also leaves his roles as CEO for KDev Oncology AB and Karolinska Development's portfolio companies Aprea AB and Akinion Pharmaceuticals AB. Karolinska Development's Deputy CEO Terje Kalland is appointed Acting CEO until a new, permanent CEO is appointed.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KDEV:SS kr12.55 SEK +0.15

KDEV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KDEV.
View Industry Companies
 

Industry Analysis

KDEV

Industry Average

Valuation KDEV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 114.3x
Price/Book 0.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 87.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KAROLINSKA DEVELOPMENT-B, please visit www.karolinskadevelopment.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.